-
Avisi Technologies Receives FDA IDE Approval to Initiate U.S. Clinical Trial for VisiPlate Glaucoma Treatment
16 Oct 2025 10:13 GMT
… U.S. Food and Drug Administration (FDA) for its glaucoma treatment device, VisiPlate. This … truly novel approach to treating open-angle glaucoma,” said Eydie Miller-Ellis … Principal Investigator for the SAPPHIRE trial.
“With its unique materials, thin …
-
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
16 Oct 2025 10:50 GMT
… result in the development of glaucoma with damage to … of a corticosteroid medication in the treatment of patients with … Information. About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: … by the FDA, United States Drug Enforcement Administration …
-
Iantrek Launches AlloFlo Uveo in the U.S., Introducing First Surgical Treatment for Uveoscleral Pathway in Glaucoma
16 Oct 2025 03:11 GMT
… surgical treatment specifically developed to target the uveoscleral pathway in glaucoma management … often-underutilized drainage route in glaucoma treatment. Unlike traditional MIGS devices, … of AlloFlo procedures. The treatment’s clinical utility and long …
-
C2 PHARMA strengthens ophthalmic API portfolio with timolol maleate launch
15 Oct 2025 13:37 GMT
… October 2025. The US-Drug Master File (US-DMF … treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma … CEO of C2 PHARMA.
C2 PHARMA is the global leader … in ophthalmic active pharmaceutical ingredients (APIs). Founded …
-
C2 PHARMA strengthens ophthalmic API portfolio
15 Oct 2025 05:24 GMT
… October 2025. The US-Drug Master File (US-DMF) … treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma … SMS Lifesciences.
“C² PHARMA is committed to provide the … APIs to the global pharmaceutical market, with more strategic …
-
Advancing Glaucoma Treatments: A Preservative-Free Future
13 Oct 2025 11:00 GMT
… drug delivery systems, providing sustained release and improved bioavailability of active pharmaceutical … in glaucoma treatmentsgel-formulated glaucoma medicationsglaucoma treatment advancementshistorical context of glaucoma medicationsimpact of …
-
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
14 Oct 2025 12:00 GMT
… -in-human trial of the Bimatoprost Drug Pad-IOL … routinely perform minimally invasive glaucoma surgery, we believe our … medication." ABOUT THE BIM-IOL SYSTEM SpyGlass Pharma’ … durable treatment options. The SpyGlass Platform was originally developed in …
-
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
14 Oct 2025 11:00 GMT
… pursuing anti-CD40L treatment to prevent organ … SL is being developed to treat acute stress reaction … . As with any pharmaceutical under development, there are significant … glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs …
-
Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
14 Oct 2025 11:00 GMT
… expands interventional options for glaucoma surgeons and patients … of-its-kind surgical treatment targeting the uveoscleral pathway … outflow in patients with glaucoma. Unlike existing solutions, … company pioneering the development of bio-interventional …
-
SETU researcher's groundbreaking eye drops could help treat millions
14 Oct 2025 09:42 GMT
South East Technological University (SETU) scientist Dr Laurence Fitzhenry has been granted two international patents for new eye drop technologies that could be the first step in helping to transform treatment for millions of people worldwide.
The patents …